17,585 Insmed, Inc. $INSM Shares Purchased by Sumitomo Mitsui Trust Group Inc.

Sumitomo Mitsui Trust Group Inc. lifted its position in shares of Insmed, Inc. (NASDAQ:INSM) by 4.0% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 455,298 shares of the biopharmaceutical company’s stock after purchasing an additional 17,585 shares during the period. Sumitomo Mitsui Trust Group Inc. owned 0.21% of Insmed worth $51,968,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of INSM. Mirae Asset Global Investments Co. Ltd. bought a new position in Insmed during the 3rd quarter valued at approximately $3,983,000. Profund Advisors LLC grew its position in shares of Insmed by 15.1% in the 3rd quarter. Profund Advisors LLC now owns 16,806 shares of the biopharmaceutical company’s stock worth $1,918,000 after buying an additional 2,204 shares during the last quarter. ProShare Advisors LLC grew its position in shares of Insmed by 6.5% in the 3rd quarter. ProShare Advisors LLC now owns 7,572 shares of the biopharmaceutical company’s stock worth $864,000 after buying an additional 463 shares during the last quarter. Vise Technologies Inc. grew its position in shares of Insmed by 45.1% in the 3rd quarter. Vise Technologies Inc. now owns 7,097 shares of the biopharmaceutical company’s stock worth $810,000 after buying an additional 2,206 shares during the last quarter. Finally, Americana Partners LLC purchased a new position in shares of Insmed during the third quarter valued at approximately $322,000.

Insider Transactions at Insmed

In other news, COO Roger Adsett sold 239,850 shares of the company’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $133.27, for a total value of $31,964,809.50. Following the sale, the chief operating officer directly owned 98,744 shares of the company’s stock, valued at $13,159,612.88. This represents a 70.84% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director David Brennan sold 25,000 shares of Insmed stock in a transaction dated Wednesday, September 9th. The shares were sold at an average price of $124.00, for a total transaction of $3,100,000.00. Following the transaction, the director directly owned 39,238 shares of the company’s stock, valued at approximately $4,865,512. This trade represents a 38.92% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 2.10% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the company. Benchmark restated a “buy” rating on shares of Insmed in a report on Monday. Mizuho set a $154.00 price target on shares of Insmed in a report on Thursday, October 29th. Stifel Nicolaus set a $195.00 price objective on shares of Insmed in a research report on Thursday, October 29th. BMO Capital Markets reaffirmed an “outperform” rating on shares of Insmed in a research report on Tuesday, October 6th. Finally, HC Wainwright assumed coverage on shares of Insmed in a research note on Wednesday. They set a “buy” rating and a $220.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $196.52.

Insmed Trading Up 5.3%

INSM opened at $110.00 on Thursday. The company has a debt-to-equity ratio of 0.77, a quick ratio of 2.59 and a current ratio of 2.86. The business has a 50 day moving average of $111.66 and a 200-day moving average of $124.87. Insmed, Inc. has a 52 week low of $90.39 and a 52 week high of $212.75.

Insmed (NASDAQ:INSM) last issued its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.08). The firm had revenue of $524.43 million during the quarter, compared to analysts’ expectations of $500.36 million. Insmed had a negative return on equity of 96.38% and a negative net margin of 39.85%. Insmed’s revenue for the quarter was up 268.4% on a year-over-year basis. During the same period in the previous year, the company earned ($1.75) earnings per share. As a group, research analysts predict that Insmed, Inc. will post -1.77 earnings per share for the current fiscal year.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company focused on developing and commercializing therapies for serious and rare diseases. The company concentrates on conditions with significant unmet medical needs, particularly in pulmonary and infectious diseases.

Insmed’s lead commercial product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled antibacterial therapy used in the United States for adults with refractory Mycobacterium avium complex lung disease as part of a combination antibacterial regimen.